AbangeLabsSMC acceptance in grade 2 glioma sharpens the evidence signal for earlier treatment sequencing discussions. https://www.mattheneus.com/editorial/smc-vorasidenib-voranigo-acceptance-grade2-glioma-phase3-lineage-2026-03-09 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
SMC accepts vorasidenib for IDH-mutant grade 2 glioma with phase III direct evidence and PAS-linked value conditions
SMC accepted vorasidenib for eligible grade 2 astrocytoma or oligodendroglioma, citing randomized phase III progression-free survival benefit and linking cost-effectiveness to an approved patient access scheme.